- Home
- CLPR vs OTLK Comparison
CLPR vs OTLK Comparison
Compare CLPR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- OTLK
- Stock Information
- Founded
- CLPR 2015
- OTLK 2010
- Country
- CLPR United States
- OTLK United States
- Employees
- CLPR N/A
- OTLK N/A
- Industry
- CLPR Real Estate Investment Trusts
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLPR Real Estate
- OTLK Health Care
- Exchange
- CLPR Nasdaq
- OTLK Nasdaq
- Market Cap
- CLPR 57.5M
- OTLK 48.3M
- IPO Year
- CLPR 2017
- OTLK 2016
- Fundamental
- Price
- CLPR $3.98
- OTLK $2.68
- Analyst Decision
- CLPR
- OTLK Strong Buy
- Analyst Count
- CLPR 0
- OTLK 5
- Target Price
- CLPR N/A
- OTLK $9.60
- AVG Volume (30 Days)
- CLPR 94.9K
- OTLK 1.4M
- Earning Date
- CLPR 08-07-2025
- OTLK 08-14-2025
- Dividend Yield
- CLPR 9.50%
- OTLK N/A
- EPS Growth
- CLPR N/A
- OTLK N/A
- EPS
- CLPR N/A
- OTLK N/A
- Revenue
- CLPR $154,103,000.00
- OTLK $1,505,322.00
- Revenue This Year
- CLPR N/A
- OTLK N/A
- Revenue Next Year
- CLPR N/A
- OTLK $407.74
- P/E Ratio
- CLPR N/A
- OTLK N/A
- Revenue Growth
- CLPR 7.69
- OTLK N/A
- 52 Week Low
- CLPR $3.39
- OTLK $0.87
- 52 Week High
- CLPR $7.12
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- CLPR 56.25
- OTLK 76.30
- Support Level
- CLPR $3.55
- OTLK $1.95
- Resistance Level
- CLPR $4.18
- OTLK $3.02
- Average True Range (ATR)
- CLPR 0.20
- OTLK 0.19
- MACD
- CLPR 0.03
- OTLK 0.09
- Stochastic Oscillator
- CLPR 74.68
- OTLK 90.76
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.